Evidence map›Paper›PMID 40161828›Full record

ArticlebioRxiv : the preprint server for biology2025

Modulation of

Jiaxin Hu, Xin Gong, Jayanta Kundu, Dhrubajyoti Datta, Martin Egli, Muthiah Manoharan, V Vinod Mootha, David R Corey

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jiaxin HuUT Southwestern Medical Center, Departments of Pharmacology and Biochemistry, Dallas TX 75390, USA.
Xin GongUT Southwestern Medical Center, Department of Ophthalmology, Dallas, TX 75235, USA.
Jayanta KunduAlnylam Pharmaceuticals, Cambridge, MA, 04142 USA.
Dhrubajyoti DattaAlnylam Pharmaceuticals, Cambridge, MA, 04142 USA.
Martin EgliVanderbilt University, Department of Biochemistry, School of Medicine Nashville, TN 37232, USA.
Muthiah ManoharanAlnylam Pharmaceuticals, Cambridge, MA, 04142 USA.
V Vinod MoothaUT Southwestern Medical Center, Department of Ophthalmology, Dallas, TX 75235, USA.
David R CoreyUT Southwestern Medical Center, Departments of Pharmacology and Biochemistry, Dallas TX 75390, USA.

Funding

Stem Cell, Organoid and Cell Phenotyping ModuleP30EY030413 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI W MATTHEW PETROLL · 2019 to 2026
$5.9M
Recognition of Cellular Targets by single and double-stranded nucleic acidsR35GM118103 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI David R Corey · 2016 to 2026
$5.7M
Laying a Foundation for Precision Medicine for Fuchs' DystrophyR01EY022161 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI MOOTHA, VENKATESWARA VINOD · 2012 to 2024
$4.8M
NEI NIH HHS P30 EY030413NEI NIH HHS R01 EY022161NIGMS NIH HHS R35 GM118103
6 · The paper itself

Abstract

Small interfering RNAs (siRNAs) are a proven therapeutic approach for controlling gene expression in the liver. Expanding the clinical potential of RNA interference (RNAi) requires developing strategies to enhance delivery to extra-hepatic tissues. In this study we examine inhibiting

Indexed as

corneaduplex RNAintraocularintravitrealretinaretinal pigment epitheliumRNAitransthyretinTTR amyloidosis

Identifiers

PMID40161828
PMCPMC11952378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.